Biocompatible biodegradable polymeric antibacterial nanoparticles for enhancing the effects of a third-generation cephalosporin against resistant bacteria

Mushtaq, Sana; Khan, Jawad Ahmad; Rabbani, Faiz; Latif, Usman; Arfan, Muhammad; Yameen, Muhammad Arfat

doi:10.1099/jmm.0.000445

Cited by 36 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, despite the two aminoglycosides tested, amikacin and neomycin, presenting similar MWs (585.6 and 614.6 g/mol, respectively) and chemical structures (see Figure 1), the size change of their encapsulating nanostructures (625 vs. 304 nm in nanofibers and 253 vs. 209 nm in nanoparticles) and their EEs (14% vs. 40%) are very different. In this regard, the scarcity of nanoencapsulation studies for amikacin, neomycin cefotaxime and, to a lesser extent, ciprofloxacin [40][41][42][43], hampers any meaningful assessment or comparison.…”

Section: Discussionmentioning

confidence: 99%

Physico-Chemically Distinct Nanomaterials Synthesized from Derivates of a Poly(Anhydride) Diversify the Spectrum of Loadable Antibiotics

et al. 2020

View full text Add to dashboard Cite

Recent advances in the field of nanotechnology such as nanoencapsulation offer new biomedical applications, potentially increasing the scope and efficacy of therapeutic drug delivery. In addition, the discovery and development of novel biocompatible polymers increases the versatility of these encapsulating nanostructures, enabling chemical properties of the cargo and vehicle to be adapted to specific physiological requirements. Here, we evaluate the capacity of various polymeric nanostructures to encapsulate various antibiotics of different classes, with differing chemical structure. Polymers were sourced from two separate derivatives of poly(methyl vinyl ether-alt-maleic anhydride) (PMVE/MA): an acid (PMVE/MA-Ac) and a monoethyl ester (PMVE/MA-Es). Nanoencapsulation of antibiotics was attempted through electrospinning, and nanoparticle synthesis through solvent displacement, for both polymers. Solvent incompatibilities prevented the nanoencapsulation of amikacin, neomycin and ciprofloxacin in PMVE/MA-Es nanofibers. However, all compounds were successfully loaded into PMVE/MA-Es nanoparticles. Encapsulation efficiencies in nanofibers reached approximately 100% in all compatible systems; however, efficiencies varied substantially in nanoparticles systems, depending on the tested compound (14%–69%). Finally, it was confirmed that both these encapsulation processes did not alter the antimicrobial activity of any tested antibiotic against Staphylococcus aureus and Escherichia coli, supporting the viability of these approaches for nanoscale delivery of antibiotics.

show abstract

Section: Discussionmentioning

confidence: 99%

Physico-Chemically Distinct Nanomaterials Synthesized from Derivates of a Poly(Anhydride) Diversify the Spectrum of Loadable Antibiotics

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Going to organic NPs, ceftriaxone-loaded chitosan NPs were assessed on a neutropenic mouse model with good results; a 41% decrease in MRSA was observed [ 98 ]. NP capsules with a core from peppermint oil and cinnamaldehyde acted as potent antimicrobial agents with positive results against biofilms while also promoting fibroblast proliferation in a mixed bacteria/mammalian cell system, having potential applications in wound healing [ 99 ].…”

Section: Nanosystems As Antimicrobial Treatments Of Infectionsmentioning

confidence: 99%

Nanobiosystems for Antimicrobial Drug-Resistant Infections

et al. 2021

View full text Add to dashboard Cite

The worldwide increased bacterial resistance toward antimicrobial therapeutics has led investigators to search for new therapeutic options. Some of the options currently exploited to treat drug-resistant infections include drug-associated nanosystems. Additionally, the use of bacteriophages alone or in combination with drugs has been recently revisited; some studies utilizing nanosystems for bacteriophage delivery have been already reported. In this review article, we focus on nine pathogens that are the leading antimicrobial drug-resistant organisms, causing difficult-to-treat infections. For each organism, the bacteriophages and nanosystems developed or used in the last 20 years as potential treatments of pathogen-related infections are discussed. Summarizing conclusions and future perspectives related with the potential of such nano-antimicrobials for the treatment of persistent infections are finally highlighted.

show abstract

“…(Although, when considering that other publications have reported chitosan MICs in the mg/mL range [ 126 , 127 , 129 ], it is possible that this reporting of 8 µg/mL and subsequent reductions in MIC may be typographical error). Building on the advantages offered by co-delivery with antibiotics and nano-encapsulation in chitosan it has been found that it was possible to elicit strong anti-microbial effects using previously ineffective antibiotics using this strategy [ 130 , 131 , 132 , 133 ]. In other studies, the improvement to the antibiotic’s MIC was less pronounced [ 134 ], but advantages were seen when assessed against intracellular bacteria [ 135 ].…”

Section: Nanoparticle Delivery Of Antibiotics “Old Drugs New Tricmentioning

confidence: 99%

Emerging Nanomedicine Therapies to Counter the Rise of Methicillin-Resistant Staphylococcus aureus

Hibbitts

O’Leary

2018

Materials

View full text Add to dashboard Cite

In a recent report, the World Health Organisation (WHO) classified antibiotic resistance as one of the greatest threats to global health, food security, and development. Methicillin-resistant Staphylococcus aureus (MRSA) remains at the core of this threat, with persistent and resilient strains detectable in up to 90% of S. aureus infections. Unfortunately, there is a lack of novel antibiotics reaching the clinic to address the significant morbidity and mortality that MRSA is responsible for. Recently, nanomedicine strategies have emerged as a promising therapy to combat the rise of MRSA. However, these approaches have been wide-ranging in design, with few attempts to compare studies across scientific and clinical disciplines. This review seeks to reconcile this discrepancy in the literature, with specific focus on the mechanisms of MRSA infection and how they can be exploited by bioactive molecules that are delivered by nanomedicines, in addition to utilisation of the nanomaterials themselves as antibacterial agents. Finally, we discuss targeting MRSA biofilms using nano-patterning technologies and comment on future opportunities and challenges for MRSA treatment using nanomedicine.

show abstract

Biocompatible biodegradable polymeric antibacterial nanoparticles for enhancing the effects of a third-generation cephalosporin against resistant bacteria

Abstract: The synergistic effect of ceftriaxone-loaded CNPs is a useful finding for the treatment of MRSA and E. coli infections.

Cited by 36 publications

References 34 publications

Physico-Chemically Distinct Nanomaterials Synthesized from Derivates of a Poly(Anhydride) Diversify the Spectrum of Loadable Antibiotics

Physico-Chemically Distinct Nanomaterials Synthesized from Derivates of a Poly(Anhydride) Diversify the Spectrum of Loadable Antibiotics

Nanobiosystems for Antimicrobial Drug-Resistant Infections

Emerging Nanomedicine Therapies to Counter the Rise of Methicillin-Resistant Staphylococcus aureus

Contact Info

Product

Resources

About